Single Photon Emission Computed Tomography Scan as a Diagnostic Tool in Children with Cerebral Palsy Treated with Human Embryonic Stem CellsGeeta Shroff1*, Barthakur JK2, Parul Mohan3 and Harsh Mahajan4
- *Corresponding Author:
- Geeta Shroff
Director, Nutech Mediworld, H-8
Green Park Extension, New Delhi-110016, India
Tel: +91 11 26565548
Fax: +91 11 46067841
E-mail: [email protected]
Received date : March 16, 2015; Accepted date : April 11, 2015; Published date : April 16, 2015
Citation: Shroff G, Barthakur JK, Mohan P, Mahajan H (2015) Single Photon Emission Computed Tomography Scan as a Diagnostic Tool in Children with Cerebral Palsy Treated with Human Embryonic Stem Cells. J Nucl Med Radiat Ther 6:223. doi:10.4172/2155-9619.1000223
Copyright: © 2015 Shroff G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Introduction: Cerebral palsy (CP) is caused by abnormalities in the developing brain leading to an impairment of muscle coordination and movement control in the body. Neonatal hypoxic-ischemic brain injury and hypoxic ischemic encephalopathy (HIE) are major causes of CP. Neurodegenerative disorders can be treated with human embryonic stem cells (hESC). Magnetic resonance imaging (MRI), positron emission tomography and single photon emission computed tomography (SPECT) scan are some of the imaging modalities for CP, but among all SPECT scan is more sensitive in detecting abnormalities in the brain. SPECT scan is an effective tool for the detection of cerebral blood flow, cerebral impairment and local brain metabolism. The present study was conducted to evaluate the diagnostic modality of SPECT scan that can assess the patient with CP before and after hESC therapy.
Methodology: The study included the patients with CP for whom SPECT scan was performed before and after the therapy. Technetium-hexa methyl propylene aminoxime (Tc-HMPAO) SPECT scan was analyzed to assess the number of hypoperfused lesions/ areas in the brain and the percentage of improvement by hESC treatment. The patients were scored clinically using GMFCS scores.
Results: Overall, 88 patients aged 2 months to 18 years with clinical manifestations of CP had SPECT scan performed before and after the therapy. The total treatment days varied from 31 to 310 days. All the subjects showed improvement in SPECT scan. Majority of subjects (n=58) had significant SPECT scan (>60%) change, followed by moderate SPECT scan (>30% <60%) change in 15 subjects, mild scan (>10% <30%) change in 3 subjects. These patients also showed a clinical improvement as reflected in their GMFCS scores.
Conclusion: SPECT scan can be a crucial diagnostic modality to assess patients with CP.